SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-22-015737
Filing Date
2022-08-09
Accepted
2022-08-09 07:01:24
Documents
75
Period of Report
2022-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q verv-20220630.htm   iXBRL 10-Q 3280840
2 EX-10.2 verv-ex10_2.htm EX-10.2 76407
3 EX-31.1 verv-ex31_1.htm EX-31.1 19261
4 EX-31.2 verv-ex31_2.htm EX-31.2 19389
5 EX-32.1 verv-ex32_1.htm EX-32.1 11749
6 EX-32.2 verv-ex32_2.htm EX-32.2 11721
  Complete submission text file 0000950170-22-015737.txt   10164545

Data Files

Seq Description Document Type Size
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT verv-20220630_lab.xml EX-101.LAB 495063
8 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT verv-20220630.xsd EX-101.SCH 65613
9 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT verv-20220630_def.xml EX-101.DEF 253656
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT verv-20220630_pre.xml EX-101.PRE 391947
11 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT verv-20220630_cal.xml EX-101.CAL 42485
69 EXTRACTED XBRL INSTANCE DOCUMENT verv-20220630_htm.xml XML 1694755
Mailing Address 500 TECHNOLOGY SQUARE CAMBRIDGE MA 02139
Business Address 500 TECHNOLOGY SQUARE CAMBRIDGE MA 02139 (978) 501-3026
Verve Therapeutics, Inc. (Filer) CIK: 0001840574 (see all company filings)

IRS No.: 824800132 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40489 | Film No.: 221146327
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences